國立虎尾科技大學 |

The Adenosinergic System = A Non-Dopaminergic Target in Parkinson’s Disease /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	The Adenosinergic System/ edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas.
Reminder of title:	A Non-Dopaminergic Target in Parkinson’s Disease /
other author:	Morelli, Micaela.
Description:	XII, 337 p. 41 illus., 31 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Neurosciences. -
Online resource:	https://doi.org/10.1007/978-3-319-20273-0
ISBN:	9783319202730

The Adenosinergic System = A Non-Dopaminergic Target in Parkinson’s Disease /
The Adenosinergic SystemA Non-Dopaminergic Target in Parkinson’s Disease /[electronic resource] :edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas. - 1st ed. 2015. - XII, 337 p. 41 illus., 31 illus. in color.online resource. - Current Topics in Neurotoxicity,102363-9563 ;. - Current Topics in Neurotoxicity,8.

Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation – relevance for Parkinson’s disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson’s disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson’s disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline – the first approved A2A antagonist for the treatment of Parkinson’s disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.

Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant.

ISBN: 9783319202730

Standard No.: 10.1007/978-3-319-20273-0doiSubjects--Topical Terms:

593561
Neurosciences.

LC Class. No.: RC321-580

Dewey Class. No.: 612.8

The Adenosinergic System = A Non-Dopaminergic Target in Parkinson’s Disease /
LDR:03344nam a22004095i 4500 001 970624
003 DE-He213
005 20200702005301.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319202730 $9 978-3-319-20273-0
024 7 $a 10.1007/978-3-319-20273-0 $2 doi
035 $a 978-3-319-20273-0
050 4 $a RC321-580
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
245 1 4 $a The Adenosinergic System $h [electronic resource] : $b A Non-Dopaminergic Target in Parkinson’s Disease / $c edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a XII, 337 p. 41 illus., 31 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Current Topics in Neurotoxicity, $x 2363-9563 ; $v 10
505 0 $a Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation – relevance for Parkinson’s disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson’s disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson’s disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline – the first approved A2A antagonist for the treatment of Parkinson’s disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia.
520 $a Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant.
650 0 $a Neurosciences. $3 593561
650 0 $a Neurology . $3 1253459
650 2 4 $a Neurology. $3 593894
700 1 $a Morelli, Micaela. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1068879
700 1 $a Simola, Nicola. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1068880
700 1 $a Wardas, Jadwiga. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1068881
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319202723
776 0 8 $i Printed edition: $z 9783319202747
776 0 8 $i Printed edition: $z 9783319371863
830 0 $a Current Topics in Neurotoxicity, $x 2363-9563 ; $v 8 $3 1254942
856 4 0 $u https://doi.org/10.1007/978-3-319-20273-0
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)